Evidence map›Paper›PMID 34793581›Full record

ArticlePLoS pathogens2021

An HLA-I signature favouring KIR-educated Natural Killer cells mediates immune control of HIV in children and contrasts with the HLA-B-restricted CD8+ T-cell-mediated immune control in adults.

Vinicius A Vieira, Emily Adland, David F G Malone, Maureen P Martin, Andreas Groll, M Azim Ansari, Maria C Garcia-Guerrero, Mari C Puertas, Maximilian Muenchhoff, Claudia Fortuny Guash and 12 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 22 citations in OpenAlex.

  1. Renaissance of antiviral CD8Nature reviews. Immunology · 2026
    Review
  2. Review
  3. Antiretroviral therapy blocks natural selection on protective and disease-susceptible HLA-B alleles in HIV-1 infection.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. HIV post-treatment controllers have distinct immunological and virological features.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 13 institutions in 5 countries.

Vinicius A VieiraDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-4901-0424
Emily AdlandDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.
David F G MaloneDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-9144-1941
Maureen P MartinBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
Andreas GrollDepartment of Statistics, TU Dortmund University, Dortmund, Germany.ORCID 0000-0001-6787-9118
M Azim AnsariNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Maria C Garcia-GuerreroIrsiCaixa AIDS Research Institute, Badalona, Spain.
Mari C PuertasIrsiCaixa AIDS Research Institute, Badalona, Spain.ORCID 0000-0002-6750-2318
Maximilian MuenchhoffMax von Pettenkofer Institute & Gene Center, Virology, National Reference Center for Retroviruses, LMU München, Munich, Germany.ORCID 0000-0001-7016-0470
Claudia Fortuny GuashInfectious Diseases and Systemic Inflammatory Response in Pediatrics, Infectious Diseases Unit, Department of Pediatrics, Sant Joan de Déu Hospital Research Foundation, Barcelona, Spain.
Christian BranderIrsiCaixa AIDS Research Institute, Badalona, Spain.
Javier Martinez-PicadoIrsiCaixa AIDS Research Institute, Badalona, Spain.ORCID 0000-0002-4916-2129
Alasdair BamfordGreat Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.ORCID 0000-0003-4764-229X
Gareth Tudor-WilliamsDepartment of Infectious Diseases, Imperial College, London, United Kingdom.ORCID 0000-0002-4488-849X
Thumbi Ndung'uHIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Bruce D WalkerHIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Veron RamsuranSchool of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.ORCID 0000-0003-1590-9893
John FraterNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Pieter JoosteDepartment of Paediatrics, Kimberley Hospital, Kimberley, South Africa.ORCID 0000-0002-8635-2255
Dimitra PeppaDivision of Infection and Immunity, University College London, London, United Kingdom.
Mary CarringtonBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
Philip J R GoulderDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-9842-4674
University of Oxford · GBRagon Institute of MGH, MIT and Harvard · USIrsiCaixa · ESUniversitat de Vic - Universitat Central de Catalunya · ESCentre for the AIDS Programme of Research in South Africa · ZAFrederick National Laboratory for Cancer Research · USGerman Center for Infection Research · DEGreat Ormond Street Hospital · GBImperial College London · GBKimberley Hospital · ZASpanish Clinical Research Network · ESTU Dortmund University · DEUniversity College London · GB

Funding

Exploiting Natural Killer cells in HIV/HBV co-infection to achieve eradicationR01AI155182 · NIAID · UNIVERSITY OF OXFORD · PI PEPPA, DIMITRA · 2020 to 2024
$1.9M
Maximising Cure Potential in Paediatric HIV InfectionR01AI133673 · NIAID · UNIVERSITY OF OXFORD · PI GOULDER, PHILIP J · 2017 to 2021
$1.4M
CCR NIH HHS HHSN261200800001CMedical Research Council MR/M008614/2NCI NIH HHS HHSN261200800001ENIAID NIH HHS R01 AI133673NIAID NIH HHS R01 AI155182Wellcome Trust
6 · The paper itself

Abstract

Natural Killer (NK) cells contribute to HIV control in adults, but HLA-B-mediated T-cell activity has a more substantial impact on disease outcome. However, the HLA-B molecules influencing immune control in adults have less impact on paediatric infection. To investigate the contribution NK cells make to immune control, we studied >300 children living with HIV followed over two decades in South Africa. In children, HLA-B alleles associated with adult protection or disease-susceptibility did not have significant effects, whereas Bw4 (p = 0.003) and low HLA-A expression (p = 0.002) alleles were strongly associated with immunological and viral control. In a comparator adult cohort, Bw4 and HLA-A expression contributions to HIV disease outcome were dwarfed by those of protective and disease-susceptible HLA-B molecules. We next investigated the immunophenotype and effector functions of NK cells in a subset of these children using flow cytometry. Slow progression and better plasma viraemic control were also associated with high frequencies of less terminally differentiated NKG2A+NKp46+CD56dim NK cells strongly responsive to cytokine stimulation and linked with the immunogenetic signature identified. Future studies are indicated to determine whether this signature associated with immune control in early life directly facilitates functional cure in children.

Indexed as

AdolescentCD8-Positive T-LymphocytesChildChild, PreschoolCohort StudiesHistocompatibility Antigens Class IHIV-1HIV InfectionsHLA-B AntigensHumansKiller Cells, NaturalLymphocyte ActivationReceptors, KIR3DL1Histocompatibility Antigens Class IHLA-B AntigensReceptors, KIR3DL1

Identifiers

PMID34793581
PMCPMC8639058
OpenAlexW3212821370

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.